Home › Head and Neck Squamous Cell Carcinoma › Maryland
Head and Neck Squamous Cell Carcinoma clinical trials in Maryland
22 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Maryland.
Cities in Maryland
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07667400Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Central Maryland Radiation Oncology in Howard County, Columbia
- UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT04671667Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- University of Maryland/Greenebaum Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06589804A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Central Maryland Radiation Oncology, Columbia
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07418034A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Maryland School of Medicine, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06385080A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07276399FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- University of Maryland Medical Group (Site #0112), Baltimore
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06788990DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA11-0, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06953089Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 19, 2026 · NCT06223568A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07768189Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #14, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 18, 2026 · NCT06161545Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Research Site, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06535607A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- University of Maryland, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06163534Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Johns Hopkins Hospital /ID# 254056, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06064877A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Upper Chesapeake Health, Bel Air
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT06088381A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.